Skip to main content

Table 1 Baseline Demographic and Clinical Characteristics of Randomized Participants Classified as Nonremitters During Prior MPH Treatment

From: Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysis

Participant Age (years) Sex Weight (kg) Medication Total Daily Dose (mg/day) Average Daily Dose (mg/kg) Screening ADHD-RS-IV Total Score
1 6 F 22.68 OROS MPH* ≥ 30 ≥ 1.0 50
2 7 M 29.48 ER MPH 20 < 1.0 20
3 7 F 44.45 OROS MPH 36 < 1.0 28
4 8 M 44.36 OROS MPH 18 < 1.0 38
5 8 M 26.31 OROS MPH 54 ≥ 1.0 38
6 8 M 33.57 OROS MPH;
IR dMPH
54;
2.5
≥ 1.0 50
7 8 M 41.28 OROS MPH 18 < 1.0 43
8 8 F 43.68 IR MPH 30 < 1.0 50
9 9 M 29.03 ER MPH 20 < 1.0 29
10 9 M 26.76 OROS MPH 54 ≥ 1.0 39
11 9 M 31.75 MPH CD 40 ≥ 1.0 29
12 9 M 26.31 OROS MPH 27 ≥ 1.0 45
13 9 F 28.12 SR MPH 20 < 1.0 40
14 9 F 25.18 IR MPH* ≥ 50 ≥ 1.0 34
15 9 F 24.90 OROS MPH 27 ≥ 1.0 20
16 10 M 39.01 OROS MPH 54 ≥ 1.0 23
17 10 F 43.68 OROS MPH 36 < 1.0 22
18 10 F 27.67 OROS MPH 54 ≥ 1.0 37
19 10 F 29.03 IR MPH 50 ≥ 1.0 44
20 11 M 45.36 OROS MPH 72 ≥ 1.0 35
21 11 M 45.36 OROS MPH 36 < 1.0 41
22 12 M 39.46 OROS MPH 54 ≥ 1.0 45
23 12 M 34.02 OROS MPH 18 < 1.0 45
24 12 M 33.57 OROS MPH 54 ≥ 1.0 44
25 12 F 34.02 OROS MPH 36 ≥ 1.0 51
26 12 F 26.76 OROS MPH 54 ≥ 1.0 25
  1. ADHD-RS-IV = Attention-Deficit/Hyperactivity Disorder Rating Scale IV; dMPH = dexmethylphenidate; ER = extended-release; IR = immediate-release; MPH = methylphenidate; CD = controlled delivery; OROS = osmotic-release oral system; SR = sustained-release.
  2. *Exact dose of treatment for these participants could not be determined; Participant was also receiving 40 mg/d of IR mixed amphetamine salts although this was not included in the calculation of MPH dose.